Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.pSivida expands liver cancer trial
The phase IIb clinical trial commenced in October 2005 and is designed to evaluate BrachySil (32-P BioSilicon) as a potential new treatment for inoperable primary liver cancer (hepatocellular
The phase IIb clinical trial commenced in October 2005 and is designed to evaluate BrachySil (32-P BioSilicon) as a potential new treatment for inoperable primary liver cancer (hepatocellular
The first study evaluated the effect of Lunesta (eszopiclone) 3mg compared to placebo in patients with rheumatoid arthritis (RA) and co-existing insomnia. In this pilot study, nightly use
AT3022 utilizes Altea’s proprietary PassPort transdermal system, developed to deliver water-soluble small molecules, proteins, carbohydrates and oligonucleotides across the skin. AT3022 is designed to provide a safer and
The clinical trial, named MERLIN TIMI-36, is designed to evaluate the efficacy and safety of Ranexa during acute and long-term treatment in approximately 6,500 patients with non-ST elevation
On March 24, 2006, Encysive received an approvable letter from the FDA regarding the company’s new drug application (NDA) for Thelin (sitaxsentan sodium) 100mg. The FDA is currently
The trial specifically evaluated the effect of the drug combination in treatment of hepatitis C patients with early cirrhosis of the liver who failed prior therapy. Addition of
Under the expanded collaboration, Seattle Genetics will develop and optimize certain methods suitable for manufacturing and testing PSMA ADC to support studies in humans. The new agreement is
In addition to the one-time, upfront payment, UCB will also receive royalties for a period of five years based on sales and a standard manufacturing supply agreement with
The BioMerieux coagulation product line comprises a comprehensive portfolio of diagnostic tests and a complete range of automated instruments. Trinity will pay $40 million on closing, together with
HER2-positive breast cancer, which affects approximately 20% to 30% of women with breast cancer, demands special and immediate attention because the tumors are fast-growing and there is a